Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: LB01 • ACR Convergence 2025
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
Xia Zhang¹, Ruiling Feng¹, Zhanguo Li² and Jing He¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Low-dose Interleukin-2 (Ld-IL2) has shown therapeutic effect in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Various doses from 0.33 to 3.0 million units of…
Abstract Number: LB10 • ACR Convergence 2025
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Eric F. Morand¹, Cristina Arriens², Marilyn Pike³, Joan Merrill⁴, Victoria Werth⁵, Zahi Touma⁶, Razvan C. Ionitescu⁷, Masato Okada⁸, Ilias Kouris⁹, Yogita Kolekar¹⁰, Junyu Nie¹⁰, Venkat Renukuntla¹⁰, Thomas Wegman¹⁰ and Ronald van Vollenhoven¹¹, ¹Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Rheumatology, MedPharm Consulting, Inc, Bethesda, ⁴Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, ⁵University of Pennsylvania, Merion Station, Pennsylvania, ⁶University of Toronto, Toronto, Ontario, Canada, ⁷Medart Cliniq, Department of Rheumatology, Râmnicu Vâlcea, Romania, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Eli Lilly and Company Global, Basingstoke, United Kingdom, ¹⁰Bristol Myers Squibb, Princeton, ¹¹Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: There is a substantial unmet need for effective, well-tolerated therapies for patients with SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor…
Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Sitian Zang¹, Ranran Yao¹, Yan Wang¹, Danxue Zhu¹, Jing He¹ and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…
Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Andreas Reiff¹, Tadej Avcin², Bernd Jilma³, Peter Korosec⁴, Matthias Weiss-Tessbach³, Christian Schoergenhofer³, Masa Bizjak⁵, Barbara Jenko Bizjan⁶, Barbara Cugalj Kern⁵, Kim Simpfendorfer⁷, Christian Lood⁸, Tyler Artner⁹, Angelene Prasanna¹, Ken Olivier¹, Ghazaleh Gouya¹, Ralph Lambalot⁹, Abdul Hakkim¹ and Tobias Fuchs¹, ¹Neutrolis, Cambridge, Massachusetts, ²University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Medical University of Vienna, Vienna, Austria, ⁴University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, ⁵University Medical Center Ljubljana, Ljubljana, Slovenia, ⁶University of Ljubljana, Ljubljana, Slovenia, ⁷Feinstein Institutes for Medical Research, Manhasset, New York, ⁸University of Washington, Seattle, Washington, ⁹Neutrolis, Cambridge
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…
Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Bernard Rubin², Mohan Purushothaman², Wade DeJager³, Susan Macwana⁴, Joel Guthridge⁴, Stan Kamp⁴, Nancy Redinger⁴, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yangfen Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane Kamen⁸, Jill Buyon⁹, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Medical University of South Carolina, Johns Island, SC, ⁹NYU Grossman School of Medicine, New York, NY
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…
Abstract Number: 2572 • ACR Convergence 2025
Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
Hunter Sporn¹, Roshni Parulekar-Martins¹, Haopeng Wang¹, Xinran Yu¹, Jeong Yee², Youngmin Kim³, Jing Cui⁴ and Karen H. Costenbader⁵, ¹Massachusetts Institute of Technology, Boston, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Timely diagnosis and clinically meaningful stratification of systemic lupus erythematosus (SLE) remain major unmet needs. Existing risk models rely on limited genetic or lifestyle…
Abstract Number: 2459 • ACR Convergence 2025
Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Milena Delai¹, Rachel Simon¹, Eduardo Mantovani Cardoso² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) plays an important role in the immunomodulation of Systemic Lupus Erythematosus (SLE), reducing the risk of flares and overall mortality. However, long-term…
Abstract Number: 2442 • ACR Convergence 2025
Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Danae-Mona Nöthling¹, Kirill Anoshkin¹, Panagiotis Garantziotis¹, Laura Bucci¹, Tobias Rothe², Jule Taubmann³, Futoshi Iwata¹, Melanie Hagen¹, Andreas Wirsching¹, Simon Völkl⁴, Fabian Müller⁵, Aline Bozec¹, Andreas Mackensen⁶, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵University Hospital of Erlangen, Erlangen, Germany, ⁶Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by aberrant B cell activation and autoantibody production. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy induces a short,…
Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Michaela Harter¹, Rebecca Hetrick², James Slaven³ and Martha Rodriguez⁴, ¹Indiana University School of Medicine, Indianapolis, IN, ²Indiana University School of Medicine, Zionsville, IN, ³Indiana University School of Medicine, Indianapolis, ⁴Riley Hospital For Children At Indiana University, Carmel, IN
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…
Abstract Number: 2407 • ACR Convergence 2025
Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
Jorge Juan Fragío Gil¹, Roxana González Mazario², Pablo Martínez Calabuig³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Isabel Martínez Cordellat⁴, Juan José Lerma Garrido⁴ and Cristina Campos Fernández⁵, ¹Hospital General Universitario, Valencia, Spain, ²Hospital General de Valencia, Valencia, Spain, ³Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁵Hospital General de Valencia, Valencia
Background/Purpose: One common and clinically important form of systemic lupus erythematosus (SLE) is neuropsychiatric systemic lupus erythematosus (NPSLE). This systematic review and meta-analysis aimed to…
Abstract Number: 2390 • ACR Convergence 2025
SLE Genetic Risk Loci in the Context of Environmental Exposure: A Gene-Based Classification and Clinical Insight
Nina Oparina¹, Holme Vestin¹, Sarah Reid¹, Ahmne Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Øyvind Molberg³, Solbritt Rantapää-Dahlqvist⁵, Anna Rudin⁶, Chrisopher Sjöwall⁷, Anders Bengtsson⁴, Lars Rönnblom¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁷Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden
Background/Purpose: Growing evidence supports the role of chemical exposures as contributors to the development of Systemic lupus erythematosus (SLE)1. Several of the gene variants associated…
Abstract Number: 2224 • ACR Convergence 2025
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Seemal Faisal¹, Alexandra Anderson², Luke Sharrock³, James Tran⁴ and Milena Vukelic⁵, ¹Louisiana State University Health Science Center New Orleans, New Orleans, ²Louisiana State University Health Science Center New Orleans, Phoenix, AZ, ³Louisiana State University Health Science Center, New Orleans, LA, ⁴Louisiana State University Health Science Center, New Orleans, ⁵Rheumatology Fellowship Program Director Louisiana State University, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased risk of placental insufficiency and adverse pregnancy outcomes, even when the disease is clinically quiescent.…
Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Hannah Concannon¹, Jasmine Oesch², Sara Mazzarelli², Anne Fields², Keisha-Gaye O'Garo² and Rebecca Sadun³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…
Abstract Number: 1896 • ACR Convergence 2025
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
Jeong Yee¹, Emily Oakes², Candace Feldman³ and Karen H. Costenbader⁴, ¹Sungkyunkwan University, Suwon, MA, South Korea, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Electronic cigarettes, or e-cigarettes, are inhalable aerosol nicotine-delivery devices increasingly used in addition or in place of cigarettes. Cigarette smoking is strongly associated with…

1
2
3
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].